Please login to the form below

Not currently logged in
Email:
Password:

PharmaLex strikes up AI collaboration with Volv

The duo will develop pharmacovigilance products and services

PharmaLexDevelopment consulting and affairs group PharmaLex has teamed up with privately held Volv Global to bolster its pharmacovigilance business.

The project will see the duo use artificial intelligence (AI) technology, such as Volv’s predictive technologies, unassisted machine learning, paradigms and web-scale technologies, to develop products and services for PharmaLex’s clients.

Dr Thomas Dobmeyer, chief executive officer of PharmaLex, said: “The increasing volume of relevant literature in the medico-scientific domain is a challenge.

“Embedded artificial intelligence and cognitive computing technology allows for increased efficiency, especially in the area of drug adverse even monitoring.

Initially focusing on pharmacovigilance services, the project will centre in on supporting and monitoring adverse events that recorded on web forums and social media channels, regulatory intelligence platforms, patient identification for rare diseases and related services.

Christopher Rudolf, founder and chief executive officer of Volv Global, said: “We are delighted to be working with PharmaLex on the development of their pharmacovigilance (PV) solutions.

“Our innovative technology has an open design and intuitive interface, ensuring it can easily integrate into existing PV platforms.”

Article by
Gemma Jones

6th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How Transparent Is Transparency?
The second annual publication of transfer of value (TOV) data has just been publically disclosed. For those of you that it passed by, it seems to have generated very little...
Geraldine Murphy
LEO: Patients benefit from transparency
Paving the way for openness in pharma...
Running
Biosimilars: what the future looks like
Biosimilars: what the future looks like...

Infographics